Explore
Validate
Learn
Western blot
Other assayAntibody data
- Antibody Data
- Antigen structure
- References [8]
- Comments [0]
- Validations
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 16-9018-82 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD266 (TWEAK Receptor) Monoclonal Antibody (ITEM-4), Functional Grade, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The ITEM-4 antibody reacts with human TWEAK Receptor/Fn14 (fibroblast growth factor-inducible 14 kDa protein). Fn14 is distantly related to the TNFR family, containing one cysteine-rich domain in the extracellular region and a TNFR-associated factor binding domain but does not contain a death domain (DD) cytoplasmic region. Fn14 plays a role in TWEAK-induced endothelial cell migration, proliferation, and angiogenesis. TWEAK-induced cell death via Fn14 includes both apoptosis and necrosis and can be blocked by an anti-TWEAK antibody, CARL-1. Fn14 is expressed on HUVEC and in some cancer tissues but not on freshly isolated PBMCs. Fn14 mRNA expression has been identified during liver regeneration. It has been reported that ITEM-4 cross-reacts with mouse Fn14. In the mouse, Fn14 is reported to be constitutively expressed by Colon 26 cell line. The ITEM-4 antibody has been show to have blocking function. Applications Reported: This ITEM-4 antibody has been reported for use in flow cytometric analysis, western blotting, and immunohistochemical staining of frozen tissue sections. Applications Tested: This ITEM-4 antibody has been tested by flow cytometry of CD266 transfected cell lines. This can be used at less than or equal to 1 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Storage and handling: Use in a sterile environment. Filtration: 0.2 µm post-manufacturing filtered. Purity: Greater than 90%, as determined by SDS-PAGE. Endotoxin Level: Less than 0.001 ng/µg antibody, as determined by LAL assay. Aggregation: Less than 10%, as determined by HPLC.
- Reactivity
- Human, Mouse
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- ITEM-4
- Vial size
- 100 µg
- Concentration
- 1 mg/mL
- Storage
- 4° C
Submitted references Resolving the fibrotic niche of human liver cirrhosis at single-cell level.
A Paracrine Mechanism Accelerating Expansion of Human Induced Pluripotent Stem Cell-Derived Hepatic Progenitor-Like Cells.
Chronic activation of FXR in transgenic mice caused perinatal toxicity and sensitized mice to cholesterol toxicity.
Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway.
The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis.
Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death.
Multiple pathways of TWEAK-induced cell death.
Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells.
Ramachandran P, Dobie R, Wilson-Kanamori JR, Dora EF, Henderson BEP, Luu NT, Portman JR, Matchett KP, Brice M, Marwick JA, Taylor RS, Efremova M, Vento-Tormo R, Carragher NO, Kendall TJ, Fallowfield JA, Harrison EM, Mole DJ, Wigmore SJ, Newsome PN, Weston CJ, Iredale JP, Tacke F, Pollard JW, Ponting CP, Marioni JC, Teichmann SA, Henderson NC
Nature 2019 Nov;575(7783):512-518
Nature 2019 Nov;575(7783):512-518
A Paracrine Mechanism Accelerating Expansion of Human Induced Pluripotent Stem Cell-Derived Hepatic Progenitor-Like Cells.
Tsuruya K, Chikada H, Ida K, Anzai K, Kagawa T, Inagaki Y, Mine T, Kamiya A
Stem cells and development 2015 Jul 15;24(14):1691-702
Stem cells and development 2015 Jul 15;24(14):1691-702
Chronic activation of FXR in transgenic mice caused perinatal toxicity and sensitized mice to cholesterol toxicity.
Cheng Q, Inaba Y, Lu P, Xu M, He J, Zhao Y, Guo GL, Kuruba R, de la Vega R, Evans RW, Li S, Xie W
Molecular endocrinology (Baltimore, Md.) 2015 Apr;29(4):571-82
Molecular endocrinology (Baltimore, Md.) 2015 Apr;29(4):571-82
Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway.
Roos C, Wicovsky A, Müller N, Salzmann S, Rosenthal T, Kalthoff H, Trauzold A, Seher A, Henkler F, Kneitz C, Wajant H
Journal of immunology (Baltimore, Md. : 1950) 2010 Aug 1;185(3):1593-605
Journal of immunology (Baltimore, Md. : 1950) 2010 Aug 1;185(3):1593-605
The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis.
Moreno JA, Muñoz-García B, Martín-Ventura JL, Madrigal-Matute J, Orbe J, Páramo JA, Ortega L, Egido J, Blanco-Colio LM
Atherosclerosis 2009 Nov;207(1):103-10
Atherosclerosis 2009 Nov;207(1):103-10
Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death.
Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, Yagita H
Journal of immunology (Baltimore, Md. : 1950) 2003 Jan 1;170(1):341-8
Journal of immunology (Baltimore, Md. : 1950) 2003 Jan 1;170(1):341-8
Multiple pathways of TWEAK-induced cell death.
Nakayama M, Ishidoh K, Kayagaki N, Kojima Y, Yamaguchi N, Nakano H, Kominami E, Okumura K, Yagita H
Journal of immunology (Baltimore, Md. : 1950) 2002 Jan 15;168(2):734-43
Journal of immunology (Baltimore, Md. : 1950) 2002 Jan 15;168(2):734-43
Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells.
Harada N, Nakayama M, Nakano H, Fukuchi Y, Yagita H, Okumura K
Biochemical and biophysical research communications 2002 Dec 6;299(3):488-93
Biochemical and biophysical research communications 2002 Dec 6;299(3):488-93
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
